Skip to content

Clinical efficacy and safety of Wuling Capsules in the treatment of mild to moderate mood disorders with attention decline in adolescents: A real-world observational study

Clinical efficacy and safety of Wuling Capsules in the treatment of mild to moderate emotional disorders with attention decline in adolescents: A real-world observational study

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600123642
Enrollment
Unknown
Registered
2026-04-28
Start date
2026-04-28
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent patients with mild-to-moderate emotional disorders accompanied by attention decline

Interventions

The observation group consisted of adolescents with mild anxiety or depression disorders accompanied by decreased attention.:None

Sponsors

Huzhou Third Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1.Age: 12–18 years (inclusive), both genders; 2.Meet the diagnostic criteria for anxiety disorders or depressive disorders in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). 3.Hamilton Depression Rating Scale-17 (HAMD-17) > 7 or Hamilton Anxiety Rating Scale (HAMA) > 7; 4.Able to cooperate and complete the entire study; 5.Both the subject and their guardian are willing to sign the informed consent form to participate in this study;

Exclusion criteria

Exclusion criteria: 1.Patients with severe depression (with obvious suicidal tendency); 2.Patients with neuropsychiatric disorders such as intellectual disability, schizophrenia, or history of epilepsy; 3.Patients with suspected intellectual disability; 4.Patients with a history of alcohol or substance abuse; 5.Patients who have used traditional Chinese medicine for anti-anxiety, anti-depression, or sleep assistance within the past two weeks; 6.Patients who have taken benzodiazepines or azapirone drugs within the past week. 7.Patients deemed unsuitable for enrollment by the investigator for other reasons.

Design outcomes

Primary

MeasureTime frame
The measurement of attention span at the end of the 6th week of treatment, the error rate;

Secondary

MeasureTime frame
The Hamilton Depression Rating Scale - 17 scores at the 2nd and 6th weeks of treatment;The attention span measurement conducted at the 6th week of treatment;The Hamilton Anxiety Scale scores at the 2nd and 6th weeks of treatment;Comparison of the differences in SDQ scores at the 2nd and 6th weeks of treatment compared to the baseline values;

Countries

China

Contacts

Public ContactFeng Min

Huzhou Third Municipal Hospital

894087198@qq.com+86 572 226 3862

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026